Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma
- 1 November 2013
- journal article
- case report
- Published by Elsevier BV in Lung Cancer
- Vol. 82 (2), 370-372
- https://doi.org/10.1016/j.lungcan.2013.06.003
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to ErlotinibJournal of Thoracic Oncology, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating MutationsCancer Research, 2010
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating MutationsCancer Research, 2008
- Epidermal Growth Factor Receptor Mutations in Small Cell Lung CancerClinical Cancer Research, 2008
- Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutationLung Cancer, 2007
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancerCancer Science, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- EGFRMutations in Small-Cell Lung Cancers in Patients Who Have Never SmokedThe New England Journal of Medicine, 2006
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2005